Inside the research

Thermo Fisher Scientific Inc.

TMO Research profile · latest available data

Price overview

$675.00

▼ -3.39 (-0.5%)

52w hi$678.39
52w lo$437.57
Vol2.10M
As of25 Sep 2026

The Verdict

Hold

Our score +0.43

Short+0.40
Medium+0.54
Long+0.26

computed 2026-09-27

Key fundamentals

Thermo Fisher Scientific Inc.

Healthcare · Diagnostics & Research

Market cap$249.58B
Enterprise value$288.19B
Trailing P/E36.37x
Forward P/E24.51x
EV / EBITDA24.55x
P / S (ttm)5.39x
Profit margin15.0%
Return on equity13.5%
Revenue growth+10.5%
Earnings growth+9.4%
Debt / equity80.58

Layer Breakdown

LayerRawContribution
Fundamental+0.19
Sector+0.08
Technical+0.31
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

United States · www.thermofisher.com

Risk Metrics

Beta vs SPX0.79
Corr SPX0.41
Annual vol30.6%
Annual ret+9.4%
Sharpe0.31
Max DD-37.0%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$620.12
High / Low$750.00 / $520.00
Median$620.00
Analysts24
Strong Buy5
Buy19
Hold2
Sell0
Strong Sell0

Recent rating actions

2026-05-08Wells Fargo→ Overweight
2026-04-24Stifel→ Buy
2026-04-24Baird→ Outperform
2026-04-14Barclays→ Overweight
2026-04-06Evercore ISI Group→ Outperform
2026-01-30TD Cowen→ Buy

Officers & Board

DirectorR. Alexandra Keith since 2020
DirectorDebora Spar since 2019
DirectorJames Mullen since 2018
DirectorDion Weisler since 2017
DirectorLars Rebien Sørensen since 2016
DirectorC. Martin Harris since 2012
DirectorRuby Chandy since 2010
DirectorNelson Chai since 2010
DirectorMarc N. Casper since 2009
DirectorTyler Jacks since 2009
DirectorScott Sperling since 2006
DirectorJim Manzi since 2000

Material Events

DateEvent8-K
2026-07-23Earnings Release, Exhibitsread
2026-05-26Shareholder Voteread
2026-04-23Earnings Release, Exhibitsread
2026-03-24Other Material Event, Exhibitsread
2026-02-12Material Agreement, Other Material Event…read
2026-01-29Earnings Release, Exhibitsread
2026-01-12Officer / Director Changeread
2025-12-01Material Agreement, Other Material Event…read
2025-10-29Other Material Event, Exhibitsread
2025-10-22Earnings Release, Exhibitsread
2025-10-07Material Agreement, Other Material Event…read
2025-09-02Other Material Event, Exhibitsread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-11Shafer Michael DExecutive Vice PresidentOption exercise11.20K$3.47M
2026-08-11Shafer Michael DExecutive Vice PresidentSell11.20K$6.72M
2026-08-11Shafer Michael DExecutive Vice PresidentOption exercise14.30K$5.98M
2026-08-11Shafer Michael DExecutive Vice PresidentSell14.30K$8.58M
2026-08-07Holmes Joseph R.VP & Chief Accounting OffOption exercise420$130.04K
2026-08-07Holmes Joseph R.VP & Chief Accounting OffSell420$245.62K
2026-08-07CASPER MARC NChairman & CEOOption exercise275$85.15K
2026-08-07CASPER MARC NChairman & CEOSell6$3.46K
2026-08-07CASPER MARC NChairman & CEOSell4$2.32K
2026-08-07CASPER MARC NChairman & CEOSell2$1.16K

Flow & Concentration

Insider 180d net-$39.11M
Insider buys / sells0 / 69
Insider biasSellers
13F holders8
Top-5 share99.2%
HHI3,963 (concentrated)

Top Holders

HolderValueShares
State Street Corp$8.44B16.83M
Fidelity / FMR LLC$7.06B14.08M
Capital Research / Capital World$1.29B2.57M
Citadel Advisors$565.38M1.13M
Millennium Management$129.39M258.07K
AQR Capital Management$128.99M257.91K
Bridgewater Associates$6.49M12.95K
T. Rowe Price Group$2.57M5.12M

As of 2026-06-30

Dividends

Yield (TTM)0.13%
$ / share (TTM)$0.90
5y CAGR+14.3%

Annual dividend per share

2021$1.04
2022$1.20
2023$1.40
2024$1.56
2025$1.72
2026$0.47

Federal Contracts

AmountAgencyDescription
$26.00MDepartment of JusticeADDITIONAL FUNDS FOR OPTION YEAR TWO.
$21.47MDepartment of JusticeFUNDING DOCUMENT FOR OY3. CONSUMABLES AND REAGENTS.
$21.24MDepartment of JusticeADDITIONAL OY1 FUNDING DOCUMENT.
$14.79MDepartment of JusticeOY1 DELIVERY ORDER FOR LIFE TECHNOLOGIES REAGENTS AND CONSUMABLES.
$9.80MDepartment of JusticeADDITIONAL FUNDING DOCUMENT FOR OPTION YEAR THREE. (OB3)
$8.51MGeneral Services AdministrationJPEO CBRND PROCUREMENT FOR FTIR AND RAMAN DEVICES
$8.13MDepartment of JusticeOPTION YEAR TWO FUNDING DOCUMENT.
$3.35MDepartment of Health and Human ServicesLAB EQUIPMENT MAINTENANCE AGREEMENT

SEC Filings

DateFormDoc
2026-08-134view
2026-08-104view
2026-08-104view
2026-08-074view
2026-08-074view
2026-08-074view
2026-07-3110-Qview
2026-07-284view
2026-07-238-Kview
2026-06-304view
2026-06-304view
2026-06-304view
2026-06-304view
2026-06-304view
2026-06-2311-Kview

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$42.86B+9.7%
Gross profit$2.62B+11.4%
Operating income$7.34B+12.9%
Net income$6.00B+51.6%
Cash from ops$8.67B+11.7%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$677.53$678.00$664.53$675.002.10M
Sep 24$660.91$682.98$655.95$678.392.10M
Sep 23$657.61$671.47$655.78$665.302.35M
Sep 22$656.41$662.87$651.54$658.522.10M
Sep 21$653.89$660.44$649.12$658.762.30M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →